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Background: Disease-specific costing studies can be used as input into cost-effectiveness analyses and provide
important information for efficient resource allocation. However, limited data availability and limited
expertise constrain such studies in low- and middle-income countries (LMICs).
Objective: To describe a step-by-step guideline for conducting disease-specific costing studies in LMICs where
data availability is limited and to illustrate how the guideline was applied in a costing study of cardiovascular
disease prevention care in rural Nigeria.
Design: The step-by-step guideline provides practical recommendations on methods and data requirements
for six sequential steps: 1) definition of the study perspective, 2) characterization of the unit of analysis, 3)
identification of cost items, 4) measurement of cost items, 5) valuation of cost items, and 6) uncertainty
analyses.
Results: We discuss the necessary tradeoffs between the accuracy of estimates and data availability constraints
at each step and illustrate how a mixed methodology of accurate bottom-up micro-costing and more feasible
approaches can be used to make optimal use of all available data. An illustrative example from Nigeria is
provided.
Conclusions: An innovative, user-friendly guideline for disease-specific costing in LMICs is presented, using a
mixed methodology to account for limited data availability. The illustrative example showed that the step-by-
step guideline can be used by healthcare professionals in LMICs to conduct feasible and accurate disease-
specific cost analyses.
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I
nsight into the costs of healthcare services is essential
for efficient resource allocation and healthcare finan-
cing (15). In many cases this is informed through
costing studies. An economic evaluation comprises an
analysis of costs (costing study) and an analysis of effects
of a healthcare intervention. In this study, ‘costing study’
refers to the cost analysis within an economic evaluation.
Costing studies can be performed across a multitude of
delivery settings, such as hospitals or primary care
centers, and at different levels ranging, for example,
from a whole hospital (69) or hospital unit (10, 11) to
a specific service within a hospital (1114). The type of
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costing study chosen is dependent on the research ques-
tion of the study, also known as the ‘decision problem’.
Examples of decision problems could be profitability of a
hospital or resources utilization within a specific depart-
ment. Disease-specific costing provides healthcare provi-
ders, policy makers, and insurance companies with
valuable information on a variety of decision problems
in healthcare, such as the assessment of resource require-
ments to provide a specific service, the assessment of
financing and delivery inefficiencies, or the identification
of cost areas for cost reductions (1, 3). To facilitate the
implementation of costing studies in healthcare, many
high-income countries have established health economic
guidelines (3, 68). However, the overriding constraint
with conducting disease-specific costing studies in low-
and middle-income countries (LMICs) is data availabi-
lity (1, 914), including the lack of accurate financial
records and incomplete patient disease registers, and a
lack of expertise to conduct costing studies. There are
very few manuals for costing studies in LMICs, and those
published do not focus primarily on disease-specific
costing (4, 6).
Health economic guidelines from high-income countries
usually comprise a stepwise process to support decisions
regarding the methods of data collection and analysis. The
steps often followed include choice of the perspective of the
cost study, choice of cost categories (unit of analysis),
identification of cost items, measuring cost items, valuing
cost items, and dealing with uncertainty (3, 68, 1517).
Each of these steps entails a trade-off between accu-
rate, patient-level cost estimates, and data availability
constraints. Health economic guidelines of high-income
countries (3, 7, 8) make use of high quality, freely available
data, which is often unavailable in LMICs resulting in the
unsuitability of such guidelines. Therefore, this paper
describes a step-by-step guideline to conducting disease-
specific costing studies in settings with limited data
availability. The step-by-step guideline is based on existing
guidelines from high-income countries (3, 7, 8) and the
World Health Organization (6) but adjusted, based on
observation in the field, to a user-friendly guideline that is
feasible to use in settings with limited data availability and
resources. A secondary objective is to illustrate how each of
these steps was applied in a study of cardiovascular disease
(CVD) prevention care in rural Nigeria.
Step-by-step guideline for disease-specific
costing
This step-by-step guideline provides practical recommen-
dations on methods and data sources in settings with data
availability constraints for six sequential steps: 1) defini-
tion of the study perspective, 2) characterization of the
unit of analysis, 3) identification of cost items, 4)
measurement of cost items, 5) valuation of cost items,
and 6) uncertainty analyses. This section describes each
of these steps, and the next section provides more details
about steps (4) measurement of cost items and (5)
valuation of cost items.
A description of each step is immediately followed by an
illustrative example, applied to Ogo Oluwa Hospital
(OOH) in rural Nigeria. OOH is a private primary health-
care center in Bacita, a rural community in Kwara State,
Nigeria. OOH has admission capability and operates
primary care outpatient clinics. In addition, the QUality
Improvement Cardiovascular Care Kwara-I (QUICK-I)
project was rolled out in OOH in 2010. A description of the
QUICK-I project can be found in detail elsewhere (18). In
short, the project aims to evaluate the operational and
financial feasibility of providing CVD prevention care
according to international guidelines. The project follows a
cohort of 349 patients who are treated for CVD risk
factors, i.e. hypertension or non-insulin-dependent dia-
betes. Our illustrative example applies to the hospital’s
CVD prevention outpatient clinic, where this step-by-step
guideline is currently applied to the costing component of
the project.
Step 1: The perspective of the cost study
The decision problem determines the perspective of the
cost study. For example, if a policy maker wants to
calculate the cost-effectiveness of treating a specific
illness, productivity losses due to illness may need to be
taken into consideration (15, 17). This societal perspec-
tive in which costs outside the formal healthcare system
are also considered is often not feasible in LMICs due to
data availability constraints. A provider perspective is
used when the cost per patient incurred by the healthcare
provider (such as a hospital) is under analysis. Up until
now, cost studies in LMIC usually rely on the provider
perspective, third party payer perspective (e.g. state-
sponsored, or insurance) or patient perspective (1, 2, 4,
1921).
Illustrative example
The decision problem of the QUICK-I study relates to
the resource requirements of providing CVD prevention
care in the hospital. This decision problem led to the
choice of a provider perspective in which only the costs
incurred by OOH were considered. Items such as travel
costs of patients, lost labor market productivity, and
other societal costs were not taken into account.
Step 2: Unit of analysis
The second step is the determination of the unit of
analysis, which is also reliant on the decision problem.
If the decision problem is the profitability of a hospital or
department, the single hospital (912), or single hospital
department (14, 22), would be the most appropriate unit of
analysis, respectively. If the decision problem relates to the
payout by an insurance provider for treatment of a speci-
fic disease, the unit of analysis should be disease-specific
Marleen E. Hendriks et al.
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(13, 23). As an increasing number of LMICs are gradually
implementing Diagnosis Related Group (DRG) systems,
DRGs may be a particularly appropriate unit of analysis
for disease-specific costing (17). DRGs are clinically mean-
ingful groups of patients that have the same diagnosis and
similar patterns of resource consumption (24). Alternati-
vely, clinical pathways based on guidelines or daily clinical
practice in a hospital can be used to support disease-
specific costing. Within each unit of analysis specific
healthcare service activities can be identified, such as
consultations and diagnostic tests.
Illustrative example
As DRGs are not available in Kwara State, clinical
pathways for CVD prevention care were developed based
on international guidelines for CVD prevention care.
Figure 1 shows this clinical pathway with the identified
healthcare service activities for CVD prevention care, i.e.
consultations, tests, and drug treatment.
Step 3: Identification of cost items
In Step 2, healthcare service activities were identified
(such a consultations and diagnostic tests). Each health-
care service activity comprises different cost items such as
staff, equipment, consumables, and drugs. Depending on
the level of detail desired or available, the number of cost
items contained within a healthcare service activity will
vary. ‘Gross-costing’ requires relatively few resources but
provides a limited level of detail (3, 20, 25) compared to
‘micro-costing’, which provides a high level of detail but
is resource and data intense (see Fig. 2). An example of
gross-costing is if 20% of the hospitals patient population
receive treatment for CVD prevention care, 20% of total
hospital costs will be assigned to CVD prevention care.
On the other hand, micro-costing would identify cost
items in as much detail as possible.
Illustrative example
Micro-costing was employed to arrive at the most precise
cost estimates. Each healthcare service activity was
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Fig. 1. Clinical pathways with relevant healthcare service activities and cost items for CVD prevention care.
Note: Each visit consists of different healthcare service activities (consultations, diagnostic tests, drugs). Each healthcare service
activity consists of direct cost items and indirect cost items as listed in the figure. Traditional overheads include: security and
housekeeping staff, information technology, building and equipment maintenance, fuel and electricity cost, training, medical
non-CVD specific equipment, and general equipment. Context-specific overheads include: pharmacy staff, administration staff,
general consumables (non-test specific).
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divided into direct costs and indirect costs. Direct cost
items include staff involved in direct patient care,
equipment that could be assigned to a specific treatment,
consumables for specific tests, and drugs, while indirect
cost items include building and overheads (Fig. 1). As not
all cost items could be determined at the level of detail
desired, a context-specific overhead category was created.
This included, for example, pharmacy staff whose time
would usually be one of the direct patient care staff cost
items. However, since their time could not be specifically
assigned to CVD prevention care or any other disease-
specific activities, these costs were included as part of the
context-specific overhead category.
Step 4: Measurement of cost items
Measurement of cost items refers to measuring volumes
of patient utilization for the different cost items. For
example, a consultation may take 15 min of a doctors’
time, 10 min of a nurse’s time, make use of certain
equipment, and result in a number of drugs being
dispensed. Under gross-costing this step can be ignored,
as one does not measure individual cost items. The
availability and level of precision of patient utilization
data usually differs between cost items. Data often needs
to be collected from multiple data sources (e.g. patient
registers and records, expert opinion, laboratory and
pharmacy registers, insurance utilization databases, da-
tabases of ongoing studies). Where patient utilization
data is not available, data collection tools need to be
developed (e.g. Staff Activity Log forms, in which staff
reports time spent per patient). There can also be other
expenditures (e.g. capital projects) that must be ac-
counted for in the data collection process and in the
data analysis. The next section expands on the measure-
ment methods available for each individual cost item as
well as provides examples within the illustrative example.
Step 5: Valuation of cost items
Cost items can be valued using two approaches: top-
down or bottom-up (Fig. 2). The top-down approach
relies on comprehensive sources, such as annual financial
accounts, and divides aggregated costs by the total
number of patients. For example, annual hospital ex-
penditures on CVD prevention care drugs divided by the
number of CVD prevention care patients leads to a cost
estimate of drugs for the average patient (3, 25, 26). To
value cost items using the bottom-up approach, patient
utilization data needs to be multiplied by unit prices,
leading to cost estimates for individual patients (3, 25,
26). Possible data sources to obtain unit prices include
hospital inventories, suppliers, and manufacturers or
international sources. The next section will expand on
the bottom-up valuation methods available for each
individual cost item.
Step 6: Dealing with uncertainty
All cost estimates are subject to uncertainty (3, 27). An
important level of uncertainty concerns parameter un-
certainty. This arises due to variation around estimates of
variables, such as staff time spent per patient, and due to
assumptions on, for example, missing data. The impact of
parameter uncertainty should always be assessed using
deterministic univariate or multivariate sensitivity ana-
lyses (3, 2729). In univariate sensitivity analyses, one
parameter is changed at a time while holding the other
constant. Cost estimate parameters can be varied with a
fixed percentage or uncertainty ranges such as standard
deviations. Alternatively, point estimates can be varied
based on parameter distributions. Multivariate sensitivity
analyses vary more parameters at the same time.
Other important levels of uncertainty include model
uncertainty and generalizability uncertainty (6). Dealing
with these uncertainties falls outside the scope of this
paper.
Illustrative example
Table 1 presents examples of univariate sensitivity
analyses on a selection of parameters with a high level
of uncertainty. In this example, a fixed percentage of 20%
was used in all cases, but the choice in parameter
variation is often an arbitrary choice in the absence of
good quality information. Depending on the level of
accuracy of the data, other percentages could be used and
the percentage can be varied per parameter.
Measurement and valuation of cost items
The combination of the bottom-up approach and micro-
costing (bottom-up micro-costing) is considered to result
in the most accurate cost estimates for healthcare ser-
vice activities because all cost items are identified and
valued at the most detailed level. However, bottom-up
micro-costing is time and resource consuming and may not
always be feasible (1, 3, 26). Therefore, a mixed methodol-
ogy of costing is recommended (4). The mixed metho-
dology of costing applies bottom-up micro-costing to
activities which account for a large share of total costs
or to activities for which data collection is reasonably
feasible. Less accurate methods can be used for the
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Fig. 2. Methodology matrix and the level of accuracy at the
identification and valuation of cost components.
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remaining activities (i.e. top-down micro-costing and/or
gross-costing; Fig. 2). In this way, the costing methodo-
logy may be tailored to the decision problem in question.
Table 2 presents the methods, data requirements, and
calculations to measure and value cost items for disease-
specific costing using a mixed methodology.
Staff
As discussed above, bottom-up micro-costing requires
patient utilization data to be multiplied by unit prices,
leading to cost estimates for individual patients. To
calculate staff costs using this approach, staff salaries,
productive working hours, and minutes spent per patient
are required. When calculating the staff cost per con-
sultation, for instance, the number of minutes spent per
patient should be combined with staff costs per minute.
While salaries are usually available, the standard produc-
tive working hours used in high-income countries (30, 31)
often do not apply to LMICs and minutes spent per
patient are usually not available. Real productive working
hours and minutes spent per patient are preferably
observed by means of time and motion studies (staff
and patient observations), which can ascertain staff time
with the most accuracy, especially with regards to
determining staff idle time and time spent on healthcare
service activities other than direct patient care (20, 23).
Alternatively, more practical techniques such as Staff
Activity Log forms (self-reported time registration) or
staff interviews may be used (20).
Illustrative example
The bottom-up approach was used to allocate the salary
of doctors, nurses, and laboratory staff to healthcare
service activities. Unit costs per hour were calculated by
dividing their yearly salary by the number of productive
working hours per year. Productive working hours were
based on average number of shifts per month and shift
length, taking into account official leave days and an
estimation of the annual number of sick days for nurses,
doctors, and laboratory staff. A simple data collection
tool was developed to track staff activity (Table 3). This
tool included a Staff Activity Log form in which staff
reported all of their activities, time required to perform
these activities and the number of patients attended. Self-
reported data were verified through interviews and direct
observations by researchers and adjusted if needed. Costs
for pharmacy and administrative staff were included in
the overheads, since it was not feasible to record staff
activities that specifically related to CVD prevention care.
Equipment
Equipment costs per test are preferably calculated based
on annualized equipment replacement value (determined
through an annuity function) and yearly maintenance
costs divided by the number of tests performed per year
(4). The annuity function to determine the annua-
lized equipment replacement value takes into account
the purchasing price of the equipment, the life expectancy
(in life years), and the interest rate. Replacement values
(present purchasing value) can be obtained from hospital
Table 1. Illustrative example of parameter uncertainties, alternative assumptions, and sensitivity analyses
Assumption Alternative assumption Sensitivity analysis
Mark-up % similar for all services assuming
linear relation between direct and indirect
costs
CVD prevention patients might ‘consume’ less
building and overhead costs because they are
seen in an outpatient setting
Decrease building mark-up% and
traditional overhead mark-up% by
20%
Pharmacy staff and administrative staff in
indirect costs, assumes that time spent
per patient is similar for all patients
CVD prevention patients might use more
pharmacy resources: almost all patients on drugs
and often complicated drug regimes. Similar
consideration for record staff (searching for files of
chronic patients)
Increase ‘context-specific’ overhead
including records and pharmacy
mark-up% by 20%
CVD consultation: doctor costs based on
salary average medical staff
In this setting there is a lack of doctors. In private
clinics, the medical director tends to run also
patient clinics. In OOH, usually three doctors
including the medical director attend to all patients
Use both medical director salary (1/3)
and regular doctor salary (2/3) to value
costs per minute for a doctor
Productive working hours based on
contract hours
Certain staff such as doctors are overburdened
and work many more hours per week
Increase productive work hours by
20%
Interest rate16% (Central Bank) Local interest rate in rural setting for entrepreneurs
might be much higher (personal communication:
can be up to 25%)
Vary by 20%
Building value: estimated to be 8% of
building maintenance
No other data available Vary building value mark-up by920%
CVD: cardiovascular disease; OOH: Ogo Oluwa Hospital.
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accounts, local suppliers, or manufacturers. Alternatively,
historical values can be used. Country-specific interest
rates can be obtained from (inter)national sources such as
the World Bank (32), the International Monetary Fund
(33) or national central banks. Interest rates may also be
obtained from local banks. However, these interest rates
might be highly volatile in LMICs and therefore very
context-specific. The WHO-CHOICE project provides
standard life-years for general equipment such as com-
puters and generators (34), but manufacturers can also
provide information on life years of specific medical
equipment. Yearly maintenance costs and the number of
tests performed per year may be acquired from hos-
pital financial statements and patient and laboratory
registers.
If the number of tests performed per year is not
available, annuity and maintenance costs may be divided
by the total number of patients, but this assumes that all
patients use the equipment equally. Alternatively, equip-
ment costs could be regarded as part of the overhead costs.
Illustrative example
Cost of medical CVD prevention-related equipment
included costs of blood pressure devices, scales and
Table 2. Methodologies, data requirements, and calculations to measure and value cost items for disease-specific costing
Cost component Methodology Data requirements Calculations
Direct costs
Staff Bottom-up micro-costing Staff salary for staff involved in
care for specific disease
1) Yearly staff salary/yearly productive work
minutesstaff costs per minute
Productive working hours staff 2) Minutes spent per patient with specific disease
Minutes spent per patient with
specific disease
staff costs per minute
Top-down micro-costing Staff costs for specific disease Total staff costs for specific disease/total number of
Total number of activities (e.g.
consultation for CVD prevention
care)
patients with specific disease
Equipment Bottom-up micro-costing Equipment prices (purchasing
value)
1) PMTa(equipment prices, life years,
interest rates)
Interest rate
Life years
Maintenance costs
Total yearly equipment utilization
all patients
Utilization per patient with
specific disease
2) (Annuity maintenance costs)/total yearly
equipment utilizationequipment cost per test
3) Equipment cost per testutilization per patient
with specific disease
Top-down micro-costing Equipment prices
Interest rate
Life years
Maintenance costs
Total number of patients
1) PMTa(equipment prices, life years,
interest rates)
2) (Annuitymaintenance cost)/total number of
patients
Drugs and
Consumables
Bottom-up micro-costing Unit prices per drug/consumable
Utilization per patient with
specific disease
Unit prices per drug and consumableutilization per
patient with specific disease
Top-down micro-costing Total drug and consumable costs
for specific disease
Total drug and consumable costs for specific disease/
total number of patients with specific disease
Total number of patients with
specific disease
Indirect costs
Building and
overhead
Mark-up Total direct costs hospital
Total indirect costs hospital
Total direct costs hospital/total indirect
costs hospital
Inpatient day Total indirect costs hospital
Total number of inpatient days
Total indirect costs hospital/total
number of inpatient days
aPMT is an annuity calculation function in Microsoft Excel.
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stadiometers, stethoscopes, ophthalmoscopes, two la-
boratory devices for blood and urine tests, and an ECG
machine. International sources, such as the WHO-
CHOICE data (6, 34) and manufacturers, were used to
get the equipment value and useful life-years and the
Central Bank of Nigeria interest rate was uniformly
applied as the interest rate (35).
The number of tests performed per year was available
for the patients included in the QUICK-I cohort but not
available for other patients in OOH making use of this
equipment, which had to be estimated based on staff
interviews and the number of other patients. Utilization
data for medical non-CVD specific equipment such as
examination tables as well as general equipment such as
computers and generators was not available. Therefore,
the annuity of this equipment was included in the over-
head costs.
Drugs and consumables
Bottom-up micro-costing requires unit prices of drugs,
consumables, and patient utilization data. Unit prices are
usually available from hospital suppliers but individual
patient utilization data may be more difficult to obtain. If
no database is available, patient records and pharmacy
and laboratory registers may provide valuable informa-
tion but if these are not electronic, data collection can be
very time consuming.
Illustrative example
Where the hospital supplier provided itemized prices for
drugs and consumables, the QUICK-I study provided
data on patient drug utilization and test-specific con-
sumable utilization.
However, because itemized prices and individual
patient utilization were not available for general consum-
ables such as syringes and cotton swabs, yearly general
consumable costs determined from hospital administra-
tion records were included in the overhead costs.
Building
Similar to the calculation of equipment costs, building
costs are preferably determined by means of annuity costs
and maintenance costs. Annuity costs include the present
value of the building (3, 4, 36). As the present value of the
building is often not available in LMICs, the building
value may be estimated based on the yearly building
maintenance costs. For example, building maintenance
can be assumed to be 8% of the building value (36).
Yearly maintenance costs may be acquired from annual
financial accounts. Another method to determine the
present value of the building is to derive this from the
rental value of the building.
Two methods can then be used to include the yearly
building costs in the estimated costs per service: assigning
costs directly to the service or including the building costs
in the overheads. If the building costs are to be assigned
to a healthcare service activity, such as a consultation,
the number of square meters of the hospital used for that
activity, as opposed to other activities provided by the
hospital, needs to be determined. Thereafter, the sum of
annuity costs and yearly maintenance costs of this section
of the hospital should be divided by the number of
consultations per year (36). The number of activities per-
formed per year (i.e. consultations) can be determined
from patient utilization databases. Alternatively, the an-
nual building and maintenance costs can be assigned to the
general overheads. Overheads are discussed in more detail
in the next section.
Table 3. Examples of data collection tools
Data tool Data collected
Staff activity
General information Staff function, start time shift, end time shift
Regular daily activities: For each activity:
Ward round, consultation, surgery, administrative tasks Start time/end time, number of patients, patient category
(e.g. disease based)
Extra activities: For each activity:
Emergency consultations, emergency surgery, deliveries, ECG
recording, ultrasound, other specify
Start time/end time, number of patients, patient category
(e.g. disease based)
Monthly hospital expenditures
Staff Staff salary per function
Drugs Expenditures per drug category
Consumables Expenditures for laboratory consumables, other consumables
Building maintenance Monthly building maintenance expenditures
Equipment Purchase and maintenance expenditures
Other overhead Training, information technology, communication expenditures,
stationery, fuel, and electricity
Step-by-step guideline for disease-specific costing studies
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Illustrative example
The value of the building or rental prices was not
available. Therefore, we assumed that the yearly building
maintenance costs were 8% of the building value. The
number of useful life-years of the building was assumed
to be 25 years; the Central Bank of Nigeria interest rate
of 16% was applied (mean interest rate for the study
period) (35). As resource utilization of the hospital
building could not be assigned to each or any healthcare
service activity, the annuity of the building and yearly
maintenance costs were included in the overheads.
Overhead
There are several methods to allocate overhead costs to
disease-specific direct costs. A mark-up method involves
calculating a mark-up percentage by dividing the yearly
total hospital direct costs by the yearly hospital indirect
costs and then increasing the disease-specific direct costs
by this mark-up percentage. The mark-up percentage
allocation method assumes a linear relationship between
direct and indirect costs, making it a simple and feasible
method for LMICs (3, 4, 31). However, this assumption
has its limitations. For example, if a specific service
requires more than the average amount of overhead costs,
the actual indirect costs will be underestimated. Another
method often used for the allocation of overhead costs is
inpatient day allocation, in which all patients are assu-
med to have the same indirect costs per inpatient day,
regardless their actual resource use. Although alterna-
tive methods exist, such as weighted service and hourly
rate allocation (31), these are very time consuming and
therefore not feasible for LMICs.
Illustrative example
Overheads were reported separately for traditional and
context-specific overheads. Traditional overheads in-
cluded security and housekeeping staff, information
technology, building and equipment maintenance, fuel
and electricity cost, training, medical non-CVD specific
equipment and general equipment. Context-specific over-
heads included staff involved in direct patient care such
as the pharmacy staff and administrative staff but for
whom it was not feasible to measure resource use for
CVD prevention care specifically. The same applied to
general consumables such as cotton swabs and syringes.
Overheads were allocated to the direct costs using a
mark-up percentage. The mark-up method was chosen
because CVD prevention care is provided on an out-
patient basis, which makes inpatient day allocation less
suitable. Total direct and indirect hospital costs were
obtained from the monthly hospital expenditures sheet
(Table 3). Had, for example, the total yearly direct costs
of the hospital amounted to US$ 100,000, and the total
yearly indirect costs of the hospital amounted to US$
50,000 (composed of building costs US$ 9,000, tradi-
tional overheads US$ 27,000 and context-specific over-
heads US$ 14,000), the mark-up percentage would be
50%. All disease-specific direct costs would have to be
increased by 50% to include overhead costs.
Discussion
We present a step-by-step guideline, which is a feasible,
user-friendly tool for disease-specific costing in LMICs.
The step-by-step guideline is based on health economic
costing guidelines but demonstrates the need and ability
to adapt to settings, for example, with limited data
availability. These guidelines will vary depending on the
country-specific context. The step-by-step guideline pre-
sented in this paper can serve as a manual for hospital
managers and policy makers in healthcare. Cost analyses
provide a critical input into economic evaluations, which
is crucial to evaluate and understand the overall value
of treatment programs, interventions, and healthcare
policies.
The main limitation in conducting costing studies in
LMICs concerns limited and poor quality patient utiliza-
tion data, which are vital requirements for measuring
the identified cost items (914). The aim would be to
minimize data collection while maximizing the ability to
measure the difference in costs between patients (37). The
most feasible approach to achieving this aim is by making
use of a mixing-methods costing approach. Consistent
with previous studies (27, 31), we recommend applying
micro-costing to those cost items that comprise a large
share of total costs. When local data is inconsistent or
inadequate, there are possibilities to create data collection
templates, conduct interviews, and tailor existing hospital
data sources to conduct patient-level analysis (Table 3).
For example, in the case of the QUICK-I project, there
was no hospital financial registration system and annual
financial accounts were lacking. A simple sheet in Excel
was developed to track monthly hospital expenditures to
overcome this issue.
The clinical pathway approach presented in the
QUICK-I illustrative example presents a clear outline
of the hospital services (i.e. consultation, drug treatment,
laboratory testing) where costs are incurred. This is a
novel approach for disease-specific costing that allows
comparison with cost estimates in other settings that may
be following the same guidelines. The pathway approach
also allows calculating costs for different scenarios. For
instance, under the QUICK-I project, diagnostic tests are
done frequently, up to the standards of high-income
countries. However, WHO guidelines allow for less
frequent testing in lower resource settings, so costs can
be recalculated by adjusting the frequency of tests.
Furthermore, clinical pathways provide a valuable com-
parator to actual practice in those settings where guide-
lines are not being followed.
Marleen E. Hendriks et al.
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Conclusion
A mixed costing methodology can be a viable alternative
to standard, top-down, and gross-costing approaches that
are often used in LMICs settings due to (the assumed) lack
of data availability. The flexibility of a mixed methodology
allows using all available data sources and allows making
tradeoffs between more accurate bottom-up micro-costing
and more feasible approaches to measure cost items.
This leads to comprehensive disease-specific patient-level
cost estimates. This paper can be used as a guide for
hospital managers and healthcare planners in LMICs to
conduct feasible, disease-specific cost analyses with the
most accuracy possible given a lack of comprehensive data
sources.
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